Microwave expedited synthesis of 5-aminocamptothecin analogs: Inhibitors of hypoxia inducible factor HIF-1α

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 23, 2006, Pages 6082-6085

  Torregrossa, Joelle ^a   Bubley, Glenn J ^b   Jones, Graham B ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Anticancer; Camptothecin; HIF; Hypoxia; Microwave

Indexed keywords

5 (3 FLUOROBENZYLAMINO)CAMPTOTHECIN; 5 (4 FLUOROBENZYLAMINO)CAMPTOTHECIN; 5 (4 METHOXYBENZYLAMINO)CAMPTOTHECIN; 5 BETA FLUOROETHYLAMINOCAMPTOTHECIN; 5 PROPYLAMINOCAMPTOTHECIN; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; NEXAVAR; RAPAMYCIN; SORAFENIB; TOPOTECAN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MICROWAVE IRRADIATION;

CAMPTOTHECIN; CELL LINE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICROWAVES; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33750529529     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.08.103     Document Type: Article

References (22)

1. Zhong H., Semenza G.L., Simons J.W., and DeMarzo A.M. Cancer Detect. Prev. 28 (2004) 88
2. Belozerov V.E., and Van Meir E.G. Anti-Cancer Drugs 16 (2005) 901
3. Nagle D.G., and Zhou Y.-D. Curr. Drug Targets 7 (2006) 355
4. Poellinger L., and Johnson R.S. Curr. Opin. Genet. Dev. 14 (2004) 81
5. Hudson C.C., Liu M., Chaing G.G., Otterness D.M., Loomis D.C., and Kaper F. Mol. Cell. Biol. 22 (2002) 7004
6. Welsh S., Williams R., Kirkpatrick L., Paine-Murrieta G., and Powis G. Mol. Cancer Ther. 3 (2004) 233
7. Rathmel W.K., Wright T.M., and Fini B.I. Future Drugs (2005) 1031
8. Rapisarda A., Uranchimeg B., Sordet O., Pommier Y., Shoemaker R.H., and Melillo G. Cancer Res. 64 (2004) 1475
9. Wall M.E., Wani M.C., Cook C.E., Palmer K.H., McPhail A.T., and Sim G.A. J. Am. Chem. Soc. 88 (1966) 3888
10. For recent approaches see:. Li Q.-Y., Zu Y.-G., Shi R.-Z., and Yao L.-P. Curr. Med. Chem. 12 (2006) 2021
11. Thomas C.J., Rahier N.J., and Hecht S.M. Bioorg. Med. Chem. Lett. 12 (2004) 1585
12. Du W. Tetrahedron 59 (2003) 8649
13. Josein H., Bom D., Curran D.P., Zheng Y.-H., and Chan T.-C. Bioorg. Med. Chem. Lett. 7 (1997) 3189
14. Zhao R., Al-Said N.H., Strenbach D.L., and Lown J.W. J. Med. Chem. 40 (1997) 216
15. Comins D.L., Baevsky M.F., and Hong H. J. Am. Chem. Soc. 114 (1992) 10971
16. Subrahmanyam D., Sarma V.M., Venkateswarlu A., Sastry T.V.R.S., Kulakarni A.P., Rao D.S., and Krishna Reddy K.V.S.R. Bioorg. Med. Chem. 7 (1999) 2013
17. 20(S) Camptothecin was supplied by Wilshire Laboratories. All compounds prepared were characterized by spectroscopic and analytical methods.
18. Qabaja G., and Jones G.B. Tetrahedron Lett. 41 (2000) 5317
19. 3), δ 8.70 (s, 1 H), 8.30 (d, J = 11 Hz, 1H), 8.05 (d, J = 11 Hz, 1H), 7.95 (t, J = 7 Hz, 1H), 7.75 (t, J = 7 Hz, 1H), 7.55 (s, 1H), 7.35-6.90 (m, 4H), 6.70 (s, 0.5H), 6.60 (s, 0.5H), 5.80-6.30 (br s, 2H), 5.60 (d, J = 16 Hz, 0.5H), 5.50 (d, J = 16 Hz, 0.5H), 5.20 (d, J = 16 Hz, 0.5H), 5.10 (d, J = 16 Hz, 0.5H), 3.90 (s, 3H), 3.27 (m, 2H), 1.70-.190 (m, 2H), 1.10-0.95 (m, 3H).
20. Cells were obtained from ATCC (Rockville, MD).
21. Zimmer M., Doucette D., Siddiqui N., and Iliopoulos O. Mol. Cancer. Res. 2 (2004) 89
22. This work was supported by a grant from the DoD Prostate Cancer Research Program [DAMD17-02-1-0254] to GBJ.